Gapping down
In reaction to disappointing earnings/guidance:
In reaction to disappointing earnings/guidance:
- ARAY -13.4%, BGG -11.4%, KEYS -9.4%, WUBA -5.4%, A -4.4%
- CSCO -1.3%, (also discloses restructuring plan, will eliminate up to 5,500 positions, representing ~7 percent of its global workforce), PLAB -1.2%
M&A news:
- MOMO -5.3% (receives letter from its Chairman and CEO stating that his buyer group would like to withdraw the non-binding going private proposal dated June 23)
Select financial related names showing weakness: BBVA -1.9%, SAN -1.7%, RBS -1.6%, DB -1%
Other news:
Other news:
- EARS -66.7% (reports top-line results from TACTT2 Trial with Keyzilen in Acute Inner Ear Tinnitus did not meet its co-primary efficacy endpoints)
- CERU -61.7% ( announces top-line results from its Phase 2 trial of its lead candidate, CRLX101, in combination with Avastin; demonstrated no statistically significant difference in median PFS)
- PTLA -15.5% (receives FDA Complete Response Letter for BLA for AndexXa)
- JNP -15.3% (reports results from phase 2b clinical trial of COL-1077 lidocaine vaginal gel in gynecologic procedure pain - did not achieve its primary and secondary endpoints)
- OMED -13.3% (prices an underwritten public offering of 5.5 mln shares of its common stock at $10.00/share)
- UIHC -1.4% (United Insurance enters into all-stock merger agreement with RDX Holding)
Analyst comments:
- IEP -4% (downgraded to Sell from Neutral at UBS)
- TWTR -2.6% (downgraded to Sell from Hold at Evercore ISI)